Combigan more cost-effective than Cosopt

Article

The fixed combination of brimonidine/timolol is more cost effective than dorzolamide/timolol, according to a study published in the September/October issue of the European Journal of Ophthalmology.

The fixed combination of brimonidine/timolol (Combigan;Allergan) is more cost effective than dorzolamide/timolol (Cosopt; Merck), according to a study published in the September/October issue of the European Journal of Ophthalmology.

A. Hommer, of the Krankenanstalt Sanatorium, Vienna, Austria, and colleagues conducted a review of the literature concerning the efficacy, tolerability and cost implications (across several European countries) of various IOP-lowering therapies administered for a three-month period.

The researchers determined equal efficacy of brimonidine 0.2% and dorzolamide 2% as either fixed combinations with or as adjunctives to timolol 0.5% therapy. At three and 12 months, however, the brominidine/timolol fixed combination proved to be the least costly option. Brimonidine as an adjunct to timolol was a more expensive alternative than the fixed combination, and dorzolamide as an adjunct to timolol represented a still more expensive option.

The team concluded that, as the efficacy was equal but the cost was lower, the brominidine/timolol fixed combination offered the greatest cost effectiveness in all countries studied of the IOP-lowering therapies reviewed.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.